Status:
ENROLLING_BY_INVITATION
Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients
Lead Sponsor:
Dow University of Health Sciences
Conditions:
Vitiligo
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB...
Detailed Description
Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department Dow university hospital. Informed consent will be obtained from all the pati...
Eligibility Criteria
Inclusion
- Patients age 18 years and above
- Patients of both genders (male and female)
- Diagnosed patients of non-segmental vitiligo involving \> 5% of BSA
Exclusion
- Pregnant and lactating women
- Concomitant active infection like tuberculosis
- Personal history of cutaneous malignancy
- Use of apremilast in the past 4 weeks
- Use of phototherapy within 4 weeks before randomization
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06593197
Start Date
January 1 2025
End Date
March 30 2027
Last Update
March 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dow International Medical College , DUHS
Karachi, Sindh, Pakistan